Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are doing just fine, thank you, especially now that relatively balmy temperatures have unexpectedly descended on the Pharmalot campus. Although we are not abandoning our motto — “To live is to complain” — we will not kvetch about a welcome shot of warmth. In fact, this calls for a celebratory cup of stimulation and, of course, you are invited to join us. While you do, you can also peruse some items of interest to get the day started. Hope all goes well and, as always, do keep in touch …

The Senate Finance Committee invited seven major drug makers to testify before a committee hearing on drug pricing on Feb. 26, the second in a series of hearings examining prescription drug costs, STAT notes. The companies invited include AbbVie (ABBV), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), Merck (MRK), Pfizer (PFE), and Sanofi (SNY). Several of these companies initially declined a committee request to testify at the previous hearing held on Jan. 29.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.